Latest News
Press Releases
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B Bethesda, MD — March 28...
Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100 Bethesda, MD; January 6, 2024 –...
Solaxa Inc. Collaborates with National Ataxia Foundation Bethesda, MD and Minneapolis, MN;...
Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer Bethesda, MD; August 19, 2024 –...
U.S. Food and Drug Administration Grants Orphan Drug Designation to Solaxa Inc. ...
Solaxa Inc. Appoints Amy Chappel, MD, FAAN as Chief Medical Officer Bethesda, MD; January 1...
Solaxa Inc. Begins Operations as a Public Benefit Corporation Bethesda, MD; February 24, 2022 –...
News
Researchers at Penn State College of Medicine and Penn State Health Milton S. Hershey Medical Center are leading a clinical trial to evaluate whether...
When severe injury causes paralysis, the best next step depends on whether nerves have been severed or crushed: unsevered nerves...
- 1
- 2